сделать стартовой добавить в избранное карта сайта Remedium
Журнал Ремедиум
9 - 04 - 2020 [7:44]

об издании/about





книги Ремедиум/books

реклама в издании/advertising


условия использования материалов

Авторизация на сайте

Место для Вашей рекламы
Место для Вашей рекламы
Место для Вашей рекламы

Журнал "Ремедиум "№1-2-3 за 2020

Экспертная зона / Expert Area

Новые технологии в области анализа Данных реального мира (RWD): вопросы и перспективы / New Technologies in Real-World Data Analysis (RWD): challenges and potential solutions

DOI: http://dx.doi.org/10.21518/1561-5936-2020-1-2-3-3-9

М.Ю. Самсонов1, Н.О. Погребной2, Е.А. Вольская3

1 «Р-Фарм»; Россия, Москва, 2 Semantic Hub; Россия, Москва, 3 Независимый междисциплинарный Комитет по этической экспертизе клинических исследований

Данные реального мира (ДРМ – Real World Data (RWD)), дополняя традиционные рандомизированные клинические исследования, но не конкурируя с ними, позволяют получить более полное представление об использовании лекарственных средств в повседневной клинической практике. Регуляторные агентства ведущих экономик мира и производители лекарственных средств признают растущий вклад ДРМ в обеспечение понимания жизненного цикла лекарственных препаратов и потребностей пациентов. Данный обзор тенденций развития ДРМ знакомит читателя с многообразием технологических и методологических инноваций, а также потенциальных путей их применения в рамках фармацевтической индустрии.

M.Yu. Samsonov1, N.O. Pogrebnoy2, E.A. Vol’skaya3

1 R-Pharm; Moscow, Russia; 2 Semantic Hub; Moscow, Russia; 3 Independent Interdisciplinary Committee for the Ethical Review of Clinical Research

Real World Data (RWD) offer the possibility to derive a more complete understanding of the use of medicines in everyday clinical practice, complementing rather than competing with evidence from traditional randomized clinical trials. Government regulators of the world’s leading economies and pharmaceutical manufacturers recognize the growing contribution of DRM to understanding of the lifecycle of medicines and patient needs. This overview of DRM development trends provides a thorough introduction to a variety of technological and methodological innovations, as well as potential ways of their application in the pharmaceutical industry.

Список литературы /References

1. Sherman R.E., Davies K.M., Robb M.A., Hunter N.L., Califf R.M. Accelerating development of scientific evidence for medical products within the existing US regulatory framework. Nature Reviews Drug Discovery. 2017;(16):297–298. Available at: https://www.nature.com/articles/nrd.2017.25#supplementary-information.

2. Tremoulet A., Le J., Poindexter B,, Sullivan J.E., et al. Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design. Antimicrob Agents Chemother. 2014;(58):3013–3020. doi: 10.1128/AAC.02374-13

3. Borrelli F., Izzo A.A. Herb-drug interactions with St John’s wort (Hypericum perforatum): an update on clinical observations. AAPS J. 2009;(11):710–727. doi: 10.1208/s12248-009-9146-8.

4. Kish J.K., Ward M.A., Garofalo D., et al. Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval. Breast Cancer Res. 2018;(20):37. doi: 10.1186/s13058-018-0958-2.

5. Pacurariu A., Plueschke K., McGettigan P., et al. Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation. BMJ Open. 2018;(8):e023090. doi: 10.1136/bmjopen-2018-023090.

6. Cave А., Kurz Х., Arlett R. Real World data for regulatory decision making: challenges and possible solutions for Europe. Clin Pharmacol Ther. 2019;106(1):36-39. doi: 10.1002/cpt.1426.

7. US Food and Drug Administration. Framework for FDA’s Real-World Evidence Program. December 2018. Available at: https://www.fda.gov/media/120060/download. Accessed September 5, 2019.

8. Вольская Е., Александрова О. Защита персональных данных пациентов. Ремедиум. 2018;(10):6-11. doi: 10.21518/1561–5936–2018–10-6-11. Volskaya E., Aleksandrova O. Protecting personal data respecting patients’ privacy. Remedium. 2018;(10):6-11. (In Russ.) doi: 10.21518/1561–5936–2018–10-6-11.

9. PDUFA reauthorization performance goals and procedures fiscal years 2018 through 2022. Available at: https://www.fda.gov/media/99140/download.

10. https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/21st-century-cures-act.

11. https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-perspective-real-world-evidence-rwescientific-advice-emas-pcwp-hcpwp-joint_en.pdf.

12. https://hitconsultant.net/2019/02/27/state-of-ehr-data-realworld-evidence-rwe/#.XbfwcJMzbOQ.

13. Fralick M., Kesselheim A.S., Avorn J., Schneeweiss S. Use of Health Care Databases to Support Supplemental Indications of Approved Medications. JAMA Intern Med. 2018;178(1):55-63. doi: 10.1001/jamainternmed.2017.3919.

14. https://www.pipaonline.org/Interim-Guidance-Notes-on-UKData-Protection-in-Post-Marketing-Pharmacovigilance.

15. Morton S.C., Costlow M.R., Graff J.S. et al. Standards and guidelines for observational studies: quality is in the eye of the beholder. J Clin Epidemiol. 2016;(71):3–10. doi: 10.1016/j.jclinepi.2015.10.014.

16. Liu X., Rivera S.C., Faes L. et al. Reporting guidelines for clinical trials evaluating artificial intelligence interventions are needed. Nat Med. 2019;(25):1467–1468. doi: 10.1038/s41591-019-0603-3.

17. HMA. EU Medicines Agencies Network Strategy to 2020 - Working together to improve health. 2015 http://www.ema.europa.eu/docs/ en_GB/document_library/Other/2015/12/WC500199060.pdf.

18. Plueschke K., McGettigan P., Pacurariu A. et al. EU-funded initiatives for real world evidence: descriptive analysis of their characteristics and relevance for regulatory decision-making. BMJ Open. 2018;8(6):e021864. doi: 10.1136/bmjopen-2018-021864.

19. Iiro Toppila. Possibilities of machine learning and artificial intelligence in RWE studies. Future care Finland. 2018; April 8. Available at: https://futurecarefinland.fi/2018/04/possibilities-of-machinelearning-and-artificial-intelligence-in-rwe-studies/.

20. Real World Evidence Solutions Market by Component (RWD, EMR, Claim, Patient Registry, Pharmacy, Service), Application (Oncology, CVD, Neuro, Infection, Regulatory), End User (Pharma, Biotech, Medical Devices, Payers, Healthcare) – Global Forecast to 2024. Meticulous Market Research Pvt. Ltd.; 2019. 166 p. Available at: https://www.researchandmarkets.com/reports/4755940/realworld-evidence-rwe-solutions-market-by.

21. Evers M., Ghatak A., Suresh B., Westra A. et al. A vision for medical affairs in 2025. McKinsey & Company; 2019. Available at: https://www.mckinsey.com/industries/pharmaceuticals-and-medicalproducts/our-insights/a-vision-for-medical-affairs-in-2025.

22. Paparrizos J., White R.W., Horvitz E. Screening for pancreatic adenocarcinoma using signals from web search logs: Feasibility study and results. J Oncol Pract. 2016;12(8):737-744. doi: 10.1200/JOP.2015.010504.

23. National Institutes of Health, Healthcare Systems Research Collaboratory, «About us», nihcollaboratory.org. Accessed September 15, 2016.

24. Stegenga H. Finding answers in the real world. 24 March 2017. Available at: https://www.nice.org.uk/news/blog/findinganswers-in-the-real-world.

25. Bezin J., Duong M., Lassalle R. et al. The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology. PDS. 2017;26(8):954-962. doi: 10.1002/pds.4233.

26. Cavlan O., Chilukuri S., Evers M., Westra A. Real-world evidence: From activity to impact in healthcare decision making. McKinsey & Company; 2018. Available at: https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/realworld-evidence-from-activity-to-impact-in-healthcare-decisionmaking.

27. https://www.oecd.org/health/ministerial/ministerial-statement-2017.pdf.

Ключевые слова: данные реального мира, доказательства реальной практики, понимание естественного языка, проспективные исследования, структурированные и неструктурированные данные, real world data, practice-based evidence, natural language understanding, prospective studi

Вернуться назад

Архив номеров
Archive of "Remedium"

2020   2019    2018   2017   2016  2015    2014    2013    2012   2011   2010   2009   2008   2007   2006  2005    2004   2003

Издание зарегистрировано в Комитете по печати РФ
Рег. свидетельство ПИ №77-1138,
выдано 25.11.1999
об издании/about реклама/advertising подписка/subscription архив/archive контакты/contactусловия использования материалов
Яндекс цитирования
Rambler's Top100
Rambler's Top100

© Remedium 2014-2020
Все права защищены